Denali Therapeutics Regains Full Rights to DNL593 After Takeda Terminates Collaboration Agreement

On April 3, 2026, Denali Therapeutics announced that it has regained full global rights to DNL593 (PTV:PGRN) following the termination of its collaboration agreement with Takeda Pharmaceutical Company. Takeda's decision to terminate the 2018 agreement was based on strategic considerations and was not related to any safety or efficacy concerns. DNL593 is an investigational progranulin replacement therapy utilizing Denali’s Protein TransportVehicle (PTV) technology to treat frontotemporal dementia-granulin (FTD-GRN). With the termination, which becomes effective in 60 days, all rights revert to Denali, and the company will have no further financial obligations to Takeda regarding this program. Denali intends to proceed with the independent clinical development of DNL593. The program has completed enrollment of 40 participants in an ongoing Phase 1/2 study. Previous interim data from healthy volunteers showed dose-dependent increases in CSF progranulin levels and a generally well-tolerated safety profile. Denali expects to report results from the Phase 1/2 trial, including biomarker data, by the end of 2026.